AIDS Malignancy Clinical Trials Consortium (AMC)

艾滋病恶性肿瘤临床试验联盟 (AMC)

基本信息

批准号：
8336956
负责人：
RONALD T. MITSUYASU
金额：
$ 601.03万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-29 至 2015-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8336956
关键词：
AIDS Malignancy Consortium AIDS clinical trial group Accountability Acquired Immunodeficiency Syndrome Address Adolescent Africa African Area Arkansas Biological Markers Biology Cancer Trials Support Unit Cities Clinical Clinical Data Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Communities Country Decision Making Development Developmental Therapeutics Program Disease Eastern Cooperative Oncology Group Education and Outreach Enrollment Epidemic Evaluation Genetic Grant HIV Human Papillomavirus Immunologics International Intervention Kaposi Sarcoma Laboratories Leadership Lymphoma Malignant Neoplasms Mission Morbidity - disease rate National Cancer Institute National Institute of Allergy and Infectious Disease National Institute of Child Health and Human Development Oncology Group Pathologic Pathology Patients Pharmaceutical Preparations Pharmacology Population Prevention Process Protocols documentation Publications Research Research Infrastructure Research Personnel Research Training Resources Sampling Site Southwest Oncology Group Staging Strategic Planning Structure Supervision Testing Translational Research Universities authority cancer prevention cancer specimen resource cancer therapy data management improved mortality oncology operation protocol development standard of care statistical center tumor virology working group

项目摘要

The AIDS Malignancy Consortium (AMC) was established in 1995 to evaluate clinical interventions for the treatment and prevention of malignancies in HIV and to investigate the biology of malignancies in the context of Clinical trials. Since then, the AMC has conducted 31 clinical trials involving 1934 patients with primarily HIV related malignancies, 991 (51%) enrolled since the beginning of the current grant cycle in 2006. Twelve studies are currently enrolling patients or are in late stages of protocol development. Several key scientific findings have emerged from AMC studies that have led to improvements in the treatment or management of patients and has helped establish the current standard of care in some cases. The group has more than doubled the number of its publication in the current cycle compared to its first 10 years. In addition, the AMC has initiated a process to include subjects with HIV-associated cancers in resource poor countries where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. The scientific work of the group is focused in 4 disease-specific and one laboratory working groups; Kaposi's sarcoma, Lymphoma, Human Papillomavirus, Non-AIDS defining Cancers (NADC), and Laboratory and Translational Sciences Working Groups. In addition 3 resources committees support the work of the group; International, Outreach, Education and Recruitment and Laboratory (which oversees core labs in pharmacology, pathology, virology, biomarkers and developmental therapeutics). An Operations and Data Management Center (ODMC) at The EMMES Corporation, a Statistical Center at the University of Arkansas, and the Group Chair's Office at UCLA also support the AMC. Decision making authority is vested in the Group Chair and the Executive Committee (EC) with the Steering Committee providing scientific input and advice to the EC. The AMC consists of 8 core sites (including 3 combined city units) and 16 affiliated domestic sites. We are also in the process of establishing a network of international sites in resource-poor countries of Africa.

AIDS恶性财团（AMC）于1995年成立，以评估临床干预措施，以治疗和预防HIV中的恶性肿瘤，并在临床试验的背景下研究恶性肿瘤的生物学。从那时起，AMC进行了31项临床试验，涉及1934例主要与HIV相关的恶性肿瘤患者，自2006年当前拨款周期开始以来，991（51％）招募了。目前正在招募十二例患者或处于方案开发的晚期。 AMC研究已经出现了一些关键的科学发现，这些发现导致了患者治疗或管理的改善，并在某些情况下帮助建立了当前的护理标准。与头十年相比，该小组在当前周期中的出版数量增加了一倍以上。此外，AMC启动了一个过程，将与艾滋病毒相关的癌症的受试者纳入资源贫困国家，在这些国家中，艾滋病毒和癌症的流行已经大大增加。许多关键的临床和实验室研究人员参与了美国的艾滋病恶性肿瘤，使AMC成为全球主要旨在改善该人群中癌症治疗和预防癌症的主要临床试验小组。该小组的科学工作集中在4个疾病特异性和一个实验室工作组中。卡波西的肉瘤，淋巴瘤，人乳头瘤病毒，定义癌症（NADC）以及实验室和转化科学工作组的非辅助症。另外，三个资源委员会支持该小组的工作；国际，外展，教育和招聘和实验室（负责监督药理学，病理学，病毒学，生物标志物和发育疗法的核心实验室）。 Emmes Corporation的运营和数据管理中心（ODMC），阿肯色大学的统计中心以及UCLA集团主席办公室也支持AMC。决策授权授予团体主席和执行委员会（EC），指导委员会为EC提供科学意见和建议。 AMC由8个核心站点（包括3个联合城市单位）和16个附属的国内遗址组成。我们还在在非洲资源贫乏国家建立国际网站网络。